🇺🇸 FDA
Pipeline program

TGR-1202 + Obinutuzumab + Chlorambucil

TGR-GA-106

Phase 1 small_molecule completed

Quick answer

TGR-1202 + Obinutuzumab + Chlorambucil for Chronic Lymphocytic Leukemia is a Phase 1 program (small_molecule) at TG THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
TG THERAPEUTICS, INC.
Indication
Chronic Lymphocytic Leukemia
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials